Hookipa Pharma Inc to Post Q1 2025 Earnings of ($0.17) Per Share, HC Wainwright Forecasts (NASDAQ:HOOK)

Hookipa Pharma Inc (NASDAQ:HOOK) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Hookipa Pharma in a research report issued on Friday, April 26th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($0.17) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Hookipa Pharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.19) EPS.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings data on Friday, March 22nd. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $3.60 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%.

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $5.00 price target on shares of Hookipa Pharma in a research note on Monday, March 25th.

Hookipa Pharma Stock Performance

Shares of HOOK opened at $0.89 on Monday. Hookipa Pharma has a 52-week low of $0.41 and a 52-week high of $2.05. The business’s 50 day moving average price is $0.75 and its two-hundred day moving average price is $0.66. The firm has a market cap of $88.39 million, a PE ratio of -1.02 and a beta of 1.02.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.